Literature DB >> 3886400

Antihypertensive effects of urapidil and clonidine: a double-blind cross-over study.

E Kanniainen, O Heikkilä, T Jääskeläinen, M Lilja, A J Jounela.   

Abstract

The antihypertensive effects of urapidil and clonidine have been studied in a double-blind cross-over trial in 11 hypertensive outpatients with mild to moderate hypertension, at rest and during isometric exercise. Urapidil 30 mg b.i.d. significantly decreased the standing diastolic blood pressure (p less than 0.05) and the systolic blood pressure at the end of isometric exercise (p less than 0.05). Clonidine 0.075-0.15 mg b.i.d. was more effective in decreasing both systolic and diastolic blood pressure in the supine and standing positions as well as during isometric work (p less than 0.05-0.001). Urapidil caused fewer side-effects than clonidine. Overall, in the doses used urapidil had a weaker antihypertensive effect and caused fewer side-effects than clonidine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3886400     DOI: 10.1007/bf00635705

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  2 in total

1.  Investigations on the mode of action of a new antihypertensive drug, urapidil, in the isolated rat vas deferens.

Authors:  M Eltze
Journal:  Eur J Pharmacol       Date:  1979-10-26       Impact factor: 4.432

2.  [Studies on the effect of urapidil on the central nervous system and various organ functions in animal experiments (author's transl)].

Authors:  W Schoetensack; M Eltze; S Gönne; K P Kley; H G Menge; H Müller
Journal:  Arzneimittelforschung       Date:  1977
  2 in total
  3 in total

1.  Comparison of urapidil and atenolol in hypertension.

Authors:  E Török; M Wagner; M Podmaniczky
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 2.  Urapidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H D Langtry; G J Mammen; E M Sorkin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

3.  The assessment of the beta-blocking activity of urapidil: a new method.

Authors:  M J Jamieson; S H Jackson; S S Patel; A M Shepherd; H Galbraith; W Stewart; P H Flanagan
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.